Kim jesteśmyJesteśmy największym polskim producentem leków. Aktywnie działamy na rynkach Europy Środkowo-Wschodniej, Kaukazu i Azji Centralnej.
Odpowiedzialność społecznaJako największa polska firma farmaceutyczna chcemy pomagać ludziom żyć zdrowo w zdrowym świecie. Idea społecznej odpowiedzialności jest integralną częścią strategii zarządzania w naszej firmie.
Praca w PolpharmieChcesz osiągać sukcesy zawodowe? Dołącz do zespołu Polpharmy! Tu rozwijamy się na wielu płaszczyznach, również poza pracą.
We invest significant resources in the development of new products. Our domain is generic drugs, thanks to which we enable access to modern therapies for a wide group of patients. We conduct our own research and development, and we cooperate with universities and research institutes in Poland and abroad. We develop products in new, very advanced areas: ophthalmology, spirometry (asthma) and injectables (long-acting injections for the treatment of schizophrenia). Polpharma invests significant resources in the development of new products and innovative solutions
We have three R&D centres located in proximity to three manufacturing sites. See the projects and forms we specialise in: Our specializations – legend Orally Inhaled Products: Dry Powder Inhalers (DPI) Tablets: Immediate release (IR) 〉Modified release (SR, XR, DR) 〉Combinations Capsules: Hard gelatin 〉Soft gelatine (GR softgel) 〉Twist-off Eye drops: Solutions 〉Suspensions 〉Preservative free (ECO) forms Sterile injections & infusions: Long Acting Injectables (LAI) FDF DEVELOPMENT EXAMPLES ORLISTAT hard capsule 〉the only generic manufacturer in EUPROPOFOL suspension for infusion 〉successful developmentDISULFIRAM implantation tablets 〉successful developmentEYE DROPS SOLUTION ECO 〉9 multidose, preservative free (ECO) products successfully developed
290 R&D employees, including 29 with a doctorate3 R & D centresSpending on research and development in Poland: PLN 190 million in 2020; PLN 224 million in 2021PLN 2,317 million for research and development in 2000-2021Currently, Polpharma Group is conducting 170 development projectsInvestments in modern factories and laboratories – Construction of a new factory for the production of non-sterile forms of medicines in Sieradz, doubling the production capacity in this field and the development of modern inhalation medicines – Construction of a competence centre for sterile production (injectable and ophthalmic drugs) in Starogard Gdański – Construction of a new factory in Duchnice, which will provide contract production services for global biotechnology companies – A pilot line for the production of powders for inhalation and a modern laboratory for analysis in Sieradz
